A Prospective, Single-center, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Overexpressing Advanced Gastric Cancer With Disitamab Vedotin in Combination With Cadonilimab
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Cadonilimab (Primary) ; Disitamab vedotin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Jul 2024 Status changed from planning to not yet recruiting.
- 16 Oct 2023 New trial record